Variables tested for association | Kendall tau-b correl R (95% CI) | ||||
PC1 28.93% | PC3 11.93% | Severe | PC1 28.93% (in 12/19 severe) | PC3 11.93% (in 12/19 severe) | |
PC1 28.93% | – | 0.018 (−0.307 to 0.338) | −0.184 (−0.478 to 0.148) | – | 0.212 (−0.238 to 0.587) |
PC3 11.93% | 0.018 (−0.307 to 0.338) | – | 0.000 (−0.323 to 0.323) | 0.212 (−0.238 to 0.587) | – |
Severe | −0.184 (−0.478 to 0.148) | 0.000(−0.323 to 0.323) | – | – | – |
Sex | −0.022 (−0.342 to 0.303) | 0.066 (−0.262 to 0.381) | −0.031 (−0.351 to 0.294) | 0.275 (−0.174 to 0.630) | 0.110 (−0.334 to 0.514) |
Age baseline | 0.088 (−0.242 to 0.399) | −0.404 (−0.642 to 0.093)* | −0.367 (−0.617 to 0.051)* | −0.273 (−0.628 to 0.176) | −0.394 (−0.704 to 0.042) |
BMI baseline | 0.146 (−0.185 to 0.448) | −0.018 (−0.338 to 0.307) | 0.033 (−0.292 to 0.352) | 0.152 (−0.296 to 0.545) | 0.091 (−0.351 to 0.500) |
Baseline blood BASO count | 0.340 (0.020 to 0.597)* | 0.000 (−0.323 to 0.323) | 0.025 (−0.300 to 0.345) | 0.152 (−0.296 to 0.545) | 0.152 (−0.296 to 0.545) |
Baseline blood EOS count | 0.199 (−0.132 to 0.490) | −0.457 (−0.680 to 0.158)* | −0.050 (−0.367 to 0.277) | 0.198 (−0.251 to 0.578) | −0.290 (−0.639 to 0.158) |
Baseline blood neutrophil count | 0.193 (−0.138 to 0.485) | 0.053 (−0.275 to 0.369) | 0.367 (0.051 to 0.617)* | 0.061 (−0.378 to 0.477) | 0.242 (−0.208 to 0.608) |
FeNO baseline | 0.047 (−0.280 to 0.364) | −0.177 (−0.473 to 0.154) | −0.370 (−0.619 to 0.054)* | 0.109 (−0.336 to 0.513) | −0.233 (−0.601 to 0.218) |
Follow-up | 0.219 (−0.112 to 0.506) | −0.041 (−0.359 to 0.285) | −0.211 (−0.500 to 0.120) | 0.264 (−0.186 to 0.622) | −0.047 (−0.466 to 0.390) |
Change | 0.212 (−0.118 to 0.501) | 0.083 (−0.247 to 0.395) | 0.438 (0.134 to 0.666)* | 0.321 (−0.125 to 0.659) | 0.229 (−0.221 to 0.599) |
Sputum EOS % baseline | −0.068 (−0.383 to 0.260) | −0.367 (−0.617 to 0.051)* | 0.098 (−0.232 to 0.407) | −0.127 (−0.527 to 0.319) | −0.509 (−0.769 to 0.102)* |
Follow-up | −0.237 (−0.520 to 0.092) | −0.275 (−0.549 to 0.053) | −0.125 (−0.430 to 0.206) | −0.259 (−0.619 to 0.191) | −0.323 (−0.660 to 0.122) |
Change | −0.042 (−0.360 to 0.285) | 0.294 (−0.032 to 0.563) | −0.094 (−0.404 to 0.236) | 0.016 (−0.416 to 0.441) | 0.362 (−0.078 to 0.685) |
Sputum macrophage % baseline | −0.029 (−0.349 to 0.296) | 0.228 (−0.102 to 0.513) | −0.067 (−0.381 to 0.261) | −0.030 (−0.453 to 0.403) | 0.333 (−0.111 to 0.667) |
Follow-up | −0.129 (−0.434 to 0.202) | −0.199 (−0.490 to 0.132) | −0.385 (−0.629 to 0.071)* | −0.290 (−0.639 to 0.158) | −0.168 (−0.556 to 0.281) |
Change | −0.064 (−0.379 to 0.264) | −0.485 (−0.699 to 0.193)* | −0.050 (−0.367 to 0.277) | −0.061 (−0.477 to 0.378) | −0.545 (−0.789 to 0.153)* |
Sputum neutrophil % baseline | 0.018 (−0.307 to 0.338) | −0.333 (−0.592 to 0.012)* | −0.150 (−0.451 to 0.181) | −0.121 (−0.523 to 0.324) | −0.303 (−0.647 to 0.144) |
Follow-up | 0.053 (−0.275 to 0.369) | 0.333 (0.012 to 0.592)* | 0.217 (−0.114 to 0.504) | 0.182 (−0.268 to 0.566) | 0.303 (−0.144 to 0.647) |
Change | 0.181 (−0.150 to 0.476) | 0.556 (0.284 to 0.745)* | 0.067 (−0.261 to 0.381) | 0.273 (−0.176 to 0.628) | 0.455 (0.032 to 0.739)* |
Pre-BD FEV1%p baseline | −0.064 (−0.379 to 0.264) | 0.053 (−0.275 to 0.369) | −0.100 (−0.409 to 0.230) | −0.091 (−0.500 to 0.351) | 0.152 (−0.296 to 0.545) |
Follow-up | −0.135 (−0.438 to 0.197) | −0.088 (−0.399 to 0.242) | −0.284 (−0.555 to 0.043) | −0.242 (−0.608 to 0.208) | −0.061 (−0.477 to 0.378) |
Change | −0.146 (−0.448 to 0.185) | −0.333 (−0.592 to 0.012)* | −0.334 (−0.593 to 0.013)* | −0.273 (−0.628 to 0.176) | −0.455 (−0.739 to 0.032)* |
BD response baseline | −0.018 (−0.338 to 0.307) | 0.029 (−0.296 to 0.349) | 0.100 (−0.230 to 0.409) | 0.485 (0.071 to 0.756)* | 0.000 (−0.429 to 0.429) |
Follow-up | 0.135 (−0.197 to 0.438) | 0.392 (0.079 to 0.634)* | 0.000 (−0.323 to 0.323) | 0.576 (0.195 to 0.806)* | 0.515 (0.111 to 0.773)* |
Change | 0.146 (−0.185 to 0.448) | 0.146 (−0.185 to 0.448) | −0.067 (−0.381 to 0.261) | 0.121 (−0.324 to 0.523) | 0.364 (−0.077 to 0.685) |
There associations were also studied within the 12/19 severe asthma subpopulation.
*Indicates statistical significance.
BD, bronchodilator; BMI, body mass index.